Cargando…

Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy

Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jianshe, Ho, Gilbert, Masliah, Eliezer, Hashimoto, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928476/
https://www.ncbi.nlm.nih.gov/pubmed/36785484
http://dx.doi.org/10.1080/19336896.2023.2172912
_version_ 1784888658319376384
author Wei, Jianshe
Ho, Gilbert
Masliah, Eliezer
Hashimoto, Makoto
author_facet Wei, Jianshe
Ho, Gilbert
Masliah, Eliezer
Hashimoto, Makoto
author_sort Wei, Jianshe
collection PubMed
description Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolvability (aEVO) in these conditions. Hypothetically, in aEVO, protofibrils of amyloidogenic proteins (APs), including β-synuclein and β-amyloid, might form in response to diverse stressors in parental brain. Subsequently, the AP protofibrils might be transmitted to offspring via germ cells in a prion-like fashion. By virtue of the stress information conferred by protofibrillar APs, the OLs in offspring’s brain might be more resilient to forthcoming stressors, perhaps reducing MS risk. aEVO could be comparable to a gene for the inheritance of acquired characteristics. On the contrary, during ageing, MSA risk is increased through antagonistic pleiotropy. Consistently, the expression levels of APs are reduced in MS, but are increased in MSA compared to controls. Furthermore, β-synuclein, the non-amyloidogenic homologue of β-synuclein, might exert a buffering effect on aEVO, and abnormal β-synuclein could also increase MS and MSA disease activity. Collectively, a better understanding of the role of aEVO in the OL diseases might lead to novel interventions for such chronic degenerative conditions.
format Online
Article
Text
id pubmed-9928476
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-99284762023-02-15 Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy Wei, Jianshe Ho, Gilbert Masliah, Eliezer Hashimoto, Makoto Prion Commentaries and Views Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolvability (aEVO) in these conditions. Hypothetically, in aEVO, protofibrils of amyloidogenic proteins (APs), including β-synuclein and β-amyloid, might form in response to diverse stressors in parental brain. Subsequently, the AP protofibrils might be transmitted to offspring via germ cells in a prion-like fashion. By virtue of the stress information conferred by protofibrillar APs, the OLs in offspring’s brain might be more resilient to forthcoming stressors, perhaps reducing MS risk. aEVO could be comparable to a gene for the inheritance of acquired characteristics. On the contrary, during ageing, MSA risk is increased through antagonistic pleiotropy. Consistently, the expression levels of APs are reduced in MS, but are increased in MSA compared to controls. Furthermore, β-synuclein, the non-amyloidogenic homologue of β-synuclein, might exert a buffering effect on aEVO, and abnormal β-synuclein could also increase MS and MSA disease activity. Collectively, a better understanding of the role of aEVO in the OL diseases might lead to novel interventions for such chronic degenerative conditions. Taylor & Francis 2023-02-13 /pmc/articles/PMC9928476/ /pubmed/36785484 http://dx.doi.org/10.1080/19336896.2023.2172912 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentaries and Views
Wei, Jianshe
Ho, Gilbert
Masliah, Eliezer
Hashimoto, Makoto
Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title_full Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title_fullStr Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title_full_unstemmed Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title_short Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
title_sort differential involvement of amyloidogenic evolvability in oligodendropathies; multiple sclerosis and multiple system atrophy
topic Commentaries and Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928476/
https://www.ncbi.nlm.nih.gov/pubmed/36785484
http://dx.doi.org/10.1080/19336896.2023.2172912
work_keys_str_mv AT weijianshe differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy
AT hogilbert differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy
AT masliaheliezer differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy
AT hashimotomakoto differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy